# Exagen Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Exagen Inc). ## Overview Exagen Inc. is a U.S.-based medical technology company focused on autoimmune and rheumatic disease testing. It develops and commercializes the AVISE® portfolio, which helps physicians differentiate, diagnose, prognose, and monitor complex conditions such as connective tissue diseases, SLE, and RA. ## Products & services • AVISE® CTD testing for connective tissue disease evaluation • Autoimmune and autoimmune-related disease diagnostic panels • Prognostic and monitoring tests for rheumatology patients • Laboratory testing services sold through a specialized sales force - **AVISE® CTD and core autoimmune testing** (70%) — Flagship testing used to differentiate connective tissue diseases and related autoimmune conditions. - **Expanded biomarker-based autoimmune panels** (20%) — New biomarker content added to improve diagnostic accuracy and support broader clinical use. - **Monitoring and prognostic testing** (10%) — Tests used to follow disease activity and support treatment decisions over time. - AVISE® CTD differential diagnosis testing - Autoimmune and autoimmune-related disease test panels - Prognosis and monitoring tests for rheumatology care - Clinical laboratory testing services for physicians ## Customers Exagen sells primarily to rheumatologists and other physicians treating patients with overlapping autoimmune symptoms. It also serves primary care physicians, specialists, and healthcare providers that need more specific testing than traditional biomarker panels can offer. The business depends on physician adoption, payer reimbursement, and repeat utilization in a concentrated specialty market. - **Rheumatologists** (primary) — Primary users of AVISE® tests for differential diagnosis and monitoring of CTD, SLE, and RA. - **Primary care physicians** (secondary) — Order or refer patients with unclear autoimmune symptoms to support earlier specialist decision-making. - **Other specialists and health systems** (secondary) — Use testing to improve diagnostic clarity in multispecialty or in-house laboratory settings. - **Payers and reimbursement stakeholders** (primary) — Influence net revenue through coverage, denial rates, and collection outcomes. - Rheumatologists ordering tests for complex autoimmune cases - Primary care physicians seeking clearer referral and triage decisions - Other specialists treating patients with overlapping CTD symptoms - Healthcare providers needing better specificity than traditional biomarkers - Payers and billing systems that influence realized reimbursement ## Geography Exagen is operationally concentrated in the United States, where it runs its field sales organization and serves most of its physician customers. The company also relies on some non-U.S. suppliers, including Germany, for reagents and other materials used in testing, which creates import and tariff exposure. Its principal executive offices are in Vista, California, and its warehouse/laboratory operations are central to service continuity. - Revenue is primarily generated in the United States - Sales force is organized across five U.S. regions - Customer access is strongest in rheumatology-heavy U.S. markets - Some critical reagents and materials are sourced outside the U.S. - Germany is specifically mentioned as a foreign supplier location ## Strategy Exagen's strategy is to expand adoption of AVISE® testing by improving biomarker content, sales reach, and customer service. Management is also focused on measured territory expansion where physician demand and near-term profitable growth are most likely, while preserving cash and access to capital. - **Expand the AVISE® product portfolio** (medium-term) — New biomarkers are driving higher average selling prices and test utilization. - **Grow the field sales footprint selectively** (short-term) — More territories can increase physician access without overextending resources. - **Improve customer retention through service quality** (short-term) — Specialty diagnostics depend on physician trust, turnaround, and support. - **Maintain financing flexibility** (short-term) — The company may need external capital before operating cash flow is sufficient. - Expand AVISE® adoption through new biomarkers - Grow sales territories where demand and talent support profitable growth - Use inside sales to reach rural and outlying rheumatology markets - Strengthen customer service to improve retention and utilization - Manage liquidity through equity, debt, or collaboration funding ## Risks Exagen faces execution risk from its reliance on a narrow autoimmune testing market, payer reimbursement variability, and continued operating losses. It also has meaningful supply-chain and financing risk because critical reagents come from sole-source suppliers and the company may need external capital to fund operations. Competitive pressure from large commercial labs and traditional diagnostic methods could limit adoption if Exagen cannot sustain clinical differentiation. - **Dependence on payer reimbursement and collection estimates** [high] — Net revenue is based on expected collections, so denial rates and policy changes can move revenue and margins. - **Sole-source supplier concentration** [high] — Critical reagents, equipment, and transport-kit components come from single suppliers, increasing disruption risk. - **Need for additional capital** [high] — The company may not generate enough cash from operations to fund commercialization and R&D. - **Competitive pressure in autoimmune diagnostics** [medium] — Large labs and traditional biomarker testing can limit adoption and pricing power. - **Trade policy and foreign sourcing exposure** [medium] — Tariffs or import restrictions could raise reagent costs and compress gross margin. - Revenue can fluctuate with test volume, payer mix, and reimbursement outcomes - The company has a history of losses and may need external financing - Sole-source suppliers create supply interruption and pricing risk - Competition from large labs and traditional biomarker testing is intense - Foreign sourcing exposes costs to tariffs, trade restrictions, and logistics issues ## Accounting Exagen's revenue recognition is highly judgmental because it records revenue on an accrual basis using estimated collections by test and payor. That means changes in denial experience, reimbursement policy, or historical collection patterns can shift reported revenue between periods. Investors should also watch seasonality, variable consideration adjustments, and debt-related accounting items that can affect comparability and earnings volatility. - **Revenue recognition and variable consideration** — Can create revenue reversals or uplift in future periods - **Allowance estimates for payor collections** — Directly affects net revenue and accounts receivable - **Seasonality and period comparability** — Makes sequential comparisons less reliable - **Debt and warrant fair value accounting** — Affects net loss and financing-related line items - Revenue depends on estimated collections and variable consideration - Payor-specific allowances can materially change reported net revenue - Revenue adjustments from prior periods can create quarter-to-quarter noise - Debt, lease, and warrant accounting can affect non-operating results - Inventory and supplier-related estimates matter for cost of revenue --- *Last updated: 2026-09-24T11:05:23.616241+00:00*